BlackRock Inc. Has $6.87 Billion Stock Holdings in Eli Lilly And Co (NYSE:LLY)

BlackRock Inc. increased its holdings in Eli Lilly And Co (NYSE:LLY) by 1.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,979,145 shares of the company’s stock after purchasing an additional 898,845 shares during the quarter. BlackRock Inc. owned 6.42% of Eli Lilly And Co worth $6,866,670,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in LLY. Bessemer Group Inc. raised its holdings in shares of Eli Lilly And Co by 2,354.5% during the second quarter. Bessemer Group Inc. now owns 569,510 shares of the company’s stock valued at $63,096,000 after acquiring an additional 546,307 shares during the period. Cedar Capital LLC raised its holdings in shares of Eli Lilly And Co by 17.5% during the second quarter. Cedar Capital LLC now owns 2,459 shares of the company’s stock valued at $272,000 after acquiring an additional 367 shares during the period. Thoroughbred Financial Services LLC raised its holdings in shares of Eli Lilly And Co by 1.4% during the first quarter. Thoroughbred Financial Services LLC now owns 7,612 shares of the company’s stock valued at $988,000 after acquiring an additional 105 shares during the period. Advisor Group Inc. raised its holdings in shares of Eli Lilly And Co by 0.9% during the first quarter. Advisor Group Inc. now owns 66,256 shares of the company’s stock valued at $8,601,000 after acquiring an additional 567 shares during the period. Finally, Naples Global Advisors LLC raised its holdings in shares of Eli Lilly And Co by 1.1% during the second quarter. Naples Global Advisors LLC now owns 15,591 shares of the company’s stock valued at $1,727,000 after acquiring an additional 170 shares during the period. Institutional investors and hedge funds own 76.73% of the company’s stock.

Shares of LLY opened at $112.37 on Friday. The company’s 50 day moving average price is $112.43 and its 200 day moving average price is $115.92. Eli Lilly And Co has a 52 week low of $104.17 and a 52 week high of $132.13. The company has a market capitalization of $108.49 billion, a PE ratio of 20.25, a PEG ratio of 1.93 and a beta of 0.16. The company has a debt-to-equity ratio of 4.98, a quick ratio of 0.87 and a current ratio of 1.13.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 30th. The company reported $1.50 EPS for the quarter, beating the Zacks’ consensus estimate of $1.45 by $0.05. Eli Lilly And Co had a net margin of 33.76% and a return on equity of 70.86%. The firm had revenue of $5.64 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the firm posted $1.48 earnings per share. The firm’s revenue was up .9% on a year-over-year basis. On average, equities analysts forecast that Eli Lilly And Co will post 5.73 earnings per share for the current fiscal year.

A number of equities research analysts have recently issued reports on the stock. ValuEngine lowered shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Friday, June 28th. Bank of America set a $120.00 price target on shares of Eli Lilly And Co and gave the company a “neutral” rating in a report on Tuesday, September 10th. Nine research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Eli Lilly And Co presently has a consensus rating of “Buy” and an average price target of $122.93.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $116.37, for a total value of $24,437,700.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Alfonso G. Zulueta sold 4,500 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $117.00, for a total transaction of $526,500.00. Following the completion of the sale, the senior vice president now directly owns 33,806 shares of the company’s stock, valued at $3,955,302. The disclosure for this sale can be found here. Insiders have sold 243,452 shares of company stock worth $28,252,925 over the last ninety days. 0.11% of the stock is currently owned by insiders.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: After-Hours Trading

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply